LEADER 01706nam  2200541Ia 450 
001 9910465219203321
005 20200520144314.0
010   $a1-61209-867-3
035   $a(CKB)2560000000070426
035   $a(EBL)3018941
035   $a(SSID)ssj0000467470
035   $a(PQKBManifestationID)12169607
035   $a(PQKBTitleCode)TC0000467470
035   $a(PQKBWorkID)10490132
035   $a(PQKB)10249291
035   $a(MiAaPQ)EBC3018941
035   $a(Au-PeEL)EBL3018941
035   $a(CaPaEBR)ebr10662747
035   $a(OCoLC)847090008
035   $a(EXLCZ)992560000000070426
100   $a20090615d2009      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aCalcium channel blockers and renal disease$b[electronic resource] /$f[edited by] Nicolas Roberto Robles
210   $aHauppauge, NY $cNova Science Publishers$dc2009
215   $a1 online resource (195 p.)
225 1 $aCerebrovascular Research and Disorders
300   $aDescription based upon print version of record.
311   $a1-60741-975-0 
320   $aIncludes bibliographical references and index.
410  0$aCerebrovascular Research and Disorders
606   $aKidneys$xDiseases$xChemotherapy
606   $aCalcium$xAntagonists
608   $aElectronic books.
615  0$aKidneys$xDiseases$xChemotherapy.
615  0$aCalcium$xAntagonists.
676   $a616.6/1061
701   $aRobles$b Nicolas Roberto$0937599
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910465219203321
996   $aCalcium channel blockers and renal disease$92111880
997   $aUNINA